Introduction
============

Caveolin-1 (Cav1) was originally identified as a component of caveolae and a major tyrosine-phosphorylated substrate of Src kinase ([@bib11]; [@bib26]; [@bib38]). Caveola formation is critically dependent on expression of Cav1 as well as cavin-1/PTRF (polymerase I and transcript release factor), which along with cavin-2, -3, and -4 forms a protein family whose interaction with Cav1 impacts Cav1 stability and caveola biogenesis, morphology, and dynamics ([@bib15]; [@bib29]; [@bib1]; [@bib14]; [@bib31]). Tyrosine phosphorylation of Cav1 on Y14 is associated with Rous sarcoma virus transformation ([@bib10]; [@bib28]) and also occurs in response to growth factor stimulation and integrin-mediated mechanotransduction ([@bib30]; [@bib22]; [@bib27]; [@bib8]; [@bib36]). pCav1 promotes integrin and focal adhesion dynamics, activates RhoA GTPase, and stimulates cell migration ([@bib7]; [@bib13]; [@bib12]; [@bib21]). pCav1 also mediates raft-dependent internalization of signaling complexes upon cell detachment as well as lipid order and organization within focal adhesions ([@bib7]; [@bib9]). Tyrosine phosphorylation of Cav1 is required for EGF induction of caveola formation and E-cadherin endocytosis at epithelial junctions ([@bib33], [@bib34]). However, whether and how tyrosine phosphorylation of Cav1 impacts on caveola formation and function remain unknown.

Egr1 is a zinc finger protein and transcription factor induced by multiple cellular stimuli, including oxidative or mechanical stress ([@bib32]; [@bib44]; [@bib48]). The GC-rich consensus sequences that function as promoter-binding elements for Egr1 overlap with binding sites for the SP1 transcription factor. Competition of Egr1 with SP1 for these promoter binding sites can silence or decrease target gene expression ([@bib41]; [@bib37]; [@bib25]). Egr1 is the substrate of multiple kinases, including PKC, and when phosphorylated fails to bind target promoter DNA ([@bib16]; [@bib19]; [@bib17]). We show here that pCav1 is a mechanotransducer that induces transcriptional activation via phosphorylation of the master regulator Egr1 and of the *Cav1* and *cavin-1* genes, thereby inducing caveola formation. This therefore represents the first mechanistic link between Cav1 induction of caveolae and focal adhesion regulation by pCav1. Together with the role of caveolae as a plasma membrane reservoir to buffer membrane surges upon mechanical cell stress ([@bib42]), this study defines Cav1 as a critical mechanotransducer that regulates the cellular response to mechanical stress.

Results and discussion
======================

Cav1 Y14 phosphorylation induces caveola biogenesis through expression of Cav1 and cavin-1
------------------------------------------------------------------------------------------

The MDA-435 cancer cell line expresses low levels of Cav1 and few caveolae ([@bib24]). Stable transfection of MDA-435 cells with wild-type, dominant-negative Y14F, phosphomimetic Y14D, or positively charged Y14R C-terminal monomeric RFP (mRFP)--tagged Cav1 ([@bib12]; [@bib21]) results in stable expression of the exogenous, higher molecular weight Cav1-mRFP constructs ([Fig. 1 A](#fig1){ref-type="fig"}). Expression of wild-type Cav1-mRFP is elevated relative to endogenous Cav1 as well as to the Cav1 Y14 mutants and comparable with endogenous Cav1 levels in caveolae-expressing MDA-231 breast carcinoma cells ([Fig. S1](http://www.jcb.org/cgi/content/full/jcb.201207089/DC1){#supp1}). Interestingly, stable expression of Cav1Y14D and Y14R in MDA-435 cells results in elevated levels of endogenous Cav1 and cavin-1. Consistently, Cav1Y14D- and Y14R-expressing MDA-435 cells presented numerous caveolae and caveolae clusters by EM ([Fig. 1, B and C](#fig1){ref-type="fig"}). Surprisingly, expression of Cav1wt does not induce a significant increase in caveola density ([Fig. 1, B and C](#fig1){ref-type="fig"}). However, in Cav1^−/−^ mouse embryo fibroblasts (MEFs), in which exogenous Cav1 induces caveola formation ([@bib23]), all the Y14 Cav1-myc-mRFP constructs induce caveola formation ([Fig. S2 A](http://www.jcb.org/cgi/content/full/jcb.201207089/DC1){#supp2}). Furthermore, interaction between Cav1-mRFP and cavin-1--GFP, measured using fluorescence lifetime measurement (FLIM), is equivalent for all Y14 mutants (Fig. S2 B). This suggests that Cav1 Y14 phosphorylation impacts neither on Cav1 interaction with cavin-1 nor on the ability of Cav1 to induce caveolae. In Cav1wt-expressing MDA-435 cells, Cav1 levels either remain below the threshold for caveola formation, or endogenous cavin-1 levels are insufficient. Induction of caveolae in the Cav1Y14D and Y14R MDA-435 transfectants may be related to elevated expression of endogenous Cav1 and cavin-1.

![**Cav1 Y14 phosphomimetic induces expression of endogenous Cav1 and cavin-1 and caveolae.** (A) Cell lysates of stably transfected MDA-435 cell lines expressing dsRed, RFP-tagged wild-type Cav1 (Cav1wt), or mutant RFP-tagged Cav1Y14F, Y14D, or 14R were Western blotted for Cav1, showing expression of higher molecular weight RFP-tagged Cav1 and endogenous Cav1, as well as with antibodies to cavin-1 and β-actin. A shorter exposure of the Cav1 blot shows dramatic increase in endogenous Cav1 and cavin-1 in Cav1Y14D and Y14R MDA-435 cell lines. Densitometric quantification of exogenous Cav1-mRFP, endogenous Cav1, and cavin-1 relative to β-actin are shown (\*, P \< 0.05). (B) Representative electron micrographs of stable Cav1wt-, Y14D-, and Y14R-expressing MDA-435 cells. Cav1Y14D and Y14R cells express increased numbers of single caveolae (arrows indicate typical caveolae connected to the cell surface) and surface-connected (ruthenium red positive) caveola clusters (asterisks show connections out of the plane of the section). Arrowheads indicate clathrin-coated pits. Insets show additional images of caveolae in Cav1Y14D- and Cav1Y14R-transfected cells. PM, plasma membrane. Bars, 200 nm. (C) The number of caveolae per cell profile was quantified for stable MDA-435 transfectants (\*, P \< 0.01; \*\*, P \< 0.001). Error bars show means ± SEM.](JCB_201207089_Fig1){#fig1}

Both Cav1Y14D and Y14R functionally mimic tyrosine-phosphorylated Cav1, activating RhoA GTPase and stabilizing FAK-GFP in focal adhesions ([@bib12]; [@bib21]). RhoA GTP levels are elevated in stable Cav1wt, Y14D, and Y14R MDA-435 transfectants ([Fig. 2 A](#fig2){ref-type="fig"}). RhoA activation and recruitment of its effector Rho-associated kinase (ROCK) leads to focal adhesion maturation and actin stress fiber formation ([@bib18]); however, only the Cav1Y14D and Y14R MDA-435 transfectants present increased actin stress fibers and cell spreading ([Fig. 2 B](#fig2){ref-type="fig"}). Similar effects of both negatively charged Y14D and positively charged Y14R Cav1 mutants suggest that pCav1 is not acting via SH2 domain recruitment of Csk, Grb2, or other effectors ([@bib27]; [@bib2]) but rather through conformational changes associated with altered actin cytoskeleton organization ([@bib12]).

![**pCav1 impacts actin stress fiber formation and cell spreading.** (A) Activated RhoA-GTP was assessed by rhotekin pull-down in MDA-435 stable transfectants expressing dsRed, Cav1wt, or Y14 mutants. (B) MDA-435 stable transfectants were fluorescently labeled with Alexa Fluor 488--phalloidin, and cell spreading was determined by scan array 48 h after plating (\*, P \< 0.05; \*\*, P \< 0.001). Bar, 10 µm. (C) Effect of actin depolymerization with LatA, actin stabilization with jasplakinolide and H~2~O~2~/vanadate, prevention of cell spreading by plating cells on bacterial plates (Bac.Plate), and mechanical cell stretching (36 cycles of 30-min stretched and relaxed cycles on Bioflex 6-well plates) on endogenous Cav1, cavin-1, and β-actin levels was determined by Western blotting in MDA-435 Cav1 transfectants. (D) Cav1wt cells were not treated (NT) or treated with H~2~O~2~/vanadate, jasplakinolide (Jasp.), mechanical cell stretching, or LatA and Western blotted for pCav1, Cav1, and β-actin. Densitometric quantification is presented as a bar graph (\*, P \< 0.05). (E) MDA-435 stable transfectants were treated with H~2~O~2~/vanadate, jasplakinolide, or LatA and Western blotted for pCav1, Cav1, and β-actin. Error bars show means ± SEM.](JCB_201207089_Fig2){#fig2}

Inhibition of actin polymerization with latrunculin A (LatA) prevents, whereas actin stabilization with jasplakinolide enhances, induction of Cav1 and cavin-1 in Cav1Y14D- and Y14R-transfected MDA-435 cell lines ([Fig. 2 C](#fig2){ref-type="fig"}). Jasplakinolide treatment also induces Cav1/cavin-1 expression in Cav1wt-transfected cells but not control or Cav1Y14F-transfected cells as does stimulation of Cav1 phosphorylation by oxidative stress using hydrogen peroxide and sodium orthovanadate (H~2~O~2~/vanadate; [@bib47]). Prevention of cell spreading on bacterial plates inhibits induction of endogenous Cav1 and cavin-1 in Cav1Y14D and Y14R cells, whereas mechanical stretching (repeated \[36×\] 30-min stretched and relaxed cycles) on a FlexCell device induces Cav1 and cavin-1 in Cav1wt-transfected cells ([Fig. 2 C](#fig2){ref-type="fig"}). Tyrosine phosphorylation of both endogenous Cav1 and Cav1wt-RFP are induced by H~2~O~2~/vanadate, jasplakinolide, and mechanical stretching, whereas LatA eliminates the detectable phosphorylation of Cav1wt-RFP ([Fig. 2 D](#fig2){ref-type="fig"}). H~2~O~2~/vanadate and jasplakinolide also stimulate pCav1 expression in Cav1Y14D and Y14R, but not in dsRed or Cav1Y14F, stable MDA-435 transfectants ([Fig. 2 E](#fig2){ref-type="fig"}). Tyrosine phosphorylation of Cav1 is therefore a mechanotransducer that regulates expression of Cav1 and cavin-1 and thereby caveolae.

pCav1 regulation of Cav1 and cavin-1 is mediated by the Egr1 transcription factor
---------------------------------------------------------------------------------

Semiquantitative RT-PCR shows the significant elevation of Cav1 and, to a lesser extent, cavin-1 mRNA in Cav1Y14D- and Y14R-transfected MDA-435 cell lines ([Fig. 3 A](#fig3){ref-type="fig"}), suggesting that their expression is regulated at the transcriptional level. Egr1 is a zinc finger protein and transcription factor that binds promoter regions overlapping consensus Sp1 sites ([@bib40]; [@bib25]). RhoA activation, actin stress fiber formation, and mechanical stretching increase expression of Egr1 ([@bib32]; [@bib4]; [@bib48]). Promoter analysis identifies several putative Egr1 binding sites within GC-rich clusters overlapping SP1 binding sites in the 1,000-bp promoter region upstream of the start codon and the initial 200 bp of the first exon of both the Cav1 and cavin-1 promoters ([Fig. 3 B](#fig3){ref-type="fig"}).

![**pCav1 transcriptional regulation of Cav1 and cavin-1 is mediated by Egr1.** (A) Semiquantitative (Semi-Quant.) RT-PCR of Cav1 and cavin-1 transcript levels in stable MDA-435 Cav1 transfectants. (right) Bar graphs show normalized (against glyceraldehyde 3-phosphate dehydrogenase \[GAPDH\]) values for Cav1 and cavin-1 PCR products (\*, P \< 0.05). Error bars show means ± SEM. (B) Schematic diagrams of Cav1 and cavin-1 promoter analysis show several putative Egr1 binding sites (gray circles) within an ∼1-kb area (between −1,000 and 200) comprising the 1,000 bp upstream from the start codon and the first exon of the Cav1 and cavin-1 promoters. Egr1 sites overlap with SP1 binding sites and reside within GC-rich clusters. (C) Cell lysates of stable MDA-435 Cav1 transfectants were Western blotted for Egr1 and β-actin. Cav1Y14D- and Y14R-expressing cells present reduced levels of active nonphosphorylated (bottom band) and increased levels of the inactive phosphorylated (top band) Egr1. (bottom) Mechanical stretching (30-min stretched and relaxed cycles over 48 h) induces phosphorylation of Egr1 in Cav1wt- but not control dsRed- or dominant-negative Cav1Y14F-expressing MDA-435 stable cell lines. (D) Egr1 siRNA knockdown induces Cav1 and cavin-1 in Cav1wt- but not control dsRed- or dominant-negative Cav1Y14F-expressing MDA-435 stable cells. Ctl, control.](JCB_201207089_Fig3){#fig3}

Egr1 is a substrate of PKC and casein kinase II and, when phosphorylated, fails to avidly bind to DNA ([@bib16]; [@bib19]; [@bib17]; [@bib43]). The dramatic shift in Egr1 mobility in Cav1Y14D- and Y14R-expressing cells is indicative of its phosphorylation ([Fig. 3 C](#fig3){ref-type="fig"}; [@bib3]; [@bib6]). dsRed-, Cav1wt-, and Y14F-expressing MDA-435 cell lines express the 60-kD nonphosphorylated Egr1 protein, whereas both Cav1Y14D and Y14R transfectants have significantly higher levels of inactive phosphorylated Egr1 (∼80 kD). Egr1 phosphorylation is induced in Cav1wt- but not dsRed- or Cav1Y14F-expressing cells by mechanical stretching cycles that increase endogenous Cav1 and cavin-1 levels ([Fig. 3 C](#fig3){ref-type="fig"}). siRNA knockdown of Egr1 increases levels of endogenous Cav1 and cavin-1 but only in Cav1wt-expressing line ([Fig. 3 D](#fig3){ref-type="fig"}). No effect is observed in dsRed or Cav1Y14F stable MDA-435 cell lines, suggesting that the mechanotransduced Egr1 suppressive effect is dependent on Cav1Y14 phosphorylation. Our data suggest that mechanical stress increases Egr1 phosphorylation and inhibition of its suppressive activity. As a suppressor of both Cav1 and cavin-1 transcription, Egr1 is therefore a critical and novel regulator of caveola biogenesis.

Cotransfection of Cav1 and cavin-1 promoter luciferase reporter plasmids with an Egr1-expressing plasmid reduces the activity of both promoters ([Fig. 4 A](#fig4){ref-type="fig"}). Furthermore, Cav1 and cavin-1 promoter activity is selectively elevated in Cav1Y14D- and Y14R-expressing MDA-435 cell lines, matching the increased endogenous Cav1 and cavin-1 protein expression in these cells ([Fig. 4 B](#fig4){ref-type="fig"}). Consistently, oxidative stress (H~2~O~2~/vanadate) and mechanical stretching selectively induce Cav1 and cavin-1 promoter activity in Cav1wt- but not dsRed control- or Cav1Y14F-expressing MDA-435 cells ([Fig. 4, C and D](#fig4){ref-type="fig"}). Egr1 regulation of Cav1 and cavin-1 promoter activity is therefore pCav1 dependent.

![**Egr1 suppression of Cav1 and cavin-1 promoters is pCav1 dependent.** (A) MDA-435 cells were transiently transfected with control pRL, Cav1-luciferase (Luc), or cavin-1--luciferase promoter constructs with or without pcDNA3-Egr1 and subjected to luciferase reporter assay. (B) Stable MDA-435 Cav1 transfectants were transfected with Cav1-luciferase and cavin-1--luciferase reporter constructs and subjected to luciferase reporter assay. (C) Cav1-luciferase and cavin-1--luciferase promoter activity in nontreated (NT) or H~2~O~2~/vanadate-stimulated MDA-435 Cav1 transfectants. (D) FlexCell mechanical stretching induces Cav1 and cavin-1 promoter reporter activity in MDA-435 Cav1 transfectants. (E) CHIP assays of stable Cav1 MDA-435 transfectants showed markedly reduced promoter occupancy by Egr1 in Cav1Y14D- and Y14R-expressing stables. Negative control IgG immunoprecipitation is shown. (F) H~2~O~2~/vanadate or FlexCell mechanical stretching reduce Egr1 occupation of Cav1 and cavin-1 promoter sites in Cav1wt relative to dsRed- and Cav1Y14F-transfected MDA-435 cell lines (\*, P \< 0.05; \*\*, P \< 0.001). Ctrl, control. Error bars show means ± SEM.](JCB_201207089_Fig4){#fig4}

Occupancy of the endogenous Cav1 or cavin-1 promoters by Egr1 was determined using chromatin immunoprecipitation (CHIP) assays. In Cav1Y14D and Y14R MDA-435 cell lines, Egr1 binding to the ∼1-kb promoter region of both the *Cav1* and *cavin-1* genes is reduced relative to dsRed, Cav1wt, and Y14F lines ([Fig. 4 E](#fig4){ref-type="fig"}). Equivalent input DNA for all the lines and the lack of a PCR product in the IgG pull-down indicate the specificity of Egr1 binding. FlexCell mechanical stretching and H~2~O~2~/vanadate both selectively reduce Egr1 interaction with the promoter regions of the *Cav1* and *cavin-1* genes in Cav1wt-expressing cells ([Fig. 4 F](#fig4){ref-type="fig"}). These results suggest a feedback mechanism whereby pCav1 actively employs the Egr1 transcription factor to autoregulate its own expression as well as that of cavin-1.

Endogenous Cav1 regulates Egr1 promoter regulation in MDA-231 breast cancer cells
---------------------------------------------------------------------------------

In the metastatic MDA-231 breast carcinoma cell line that expresses elevated Cav1, pCav1, and caveolae ([@bib24]; [@bib21]), Cav1 and cavin-1 promoter activity is enhanced by actin stabilization with jasplakinolide or by H~2~O~2~/vanadate and reduced by Cav1 knockdown and LatA treatment ([Fig. 5 A](#fig5){ref-type="fig"}). The ability of jasplakinolide, H~2~O~2~/vanadate, and LatA to modulate Cav1 and cavin-1 promoter activity is Cav1 dependent as promoter activity is restored to control levels in the presence of Cav1 siRNA. CHIP assays were performed on the same set of cells transfected with control or Cav1-specific siRNAs ([Fig. 5 B](#fig5){ref-type="fig"}). Treatment with H~2~O~2~/vanadate or jasplakinolide reduces physical occupancy by Egr1 of the Cav1 and cavin-1 promoters, whereas LatA treatment enhances Egr1 promoter occupancy. However, these effects on Egr1 promoter occupancy are not observed upon siRNA knockdown of Cav1 in MDA-231 cells. Endogenous Cav1 is therefore required for Egr1 regulation of Cav1 and cavin-1 promoter activity in these metastatic breast cancer cells.

![**Transcriptional regulation of Cav1 and cavin-1 through endogenous Cav1 in metastatic MDA-231 breast cancer cells.** (A, top) Metastatic MDA-231 breast cancer cells treated with jasplakinolide (Jasp.), H~2~O~2~/vanadate (H~2~O~2~/van), or LatA or transfected with control (Ctrl si) or Cav1 siRNAs were then transiently transfected with control pRL, Cav1-luciferase (Luc), or cavin-1--luciferase constructs for 48 h and subjected to luciferase assay. (bottom) Altered promoter activity caused by jasplakinolide, H~2~O~2~/vanadate, or LatA treatment is Cav1 dependent as it is not observed in Cav1 siRNA--transfected cells. (B) CHIP assays for Egr1 binding to Cav1 and cavin-1 promoters in MDA-231 cells were performed after H~2~O~2~/vanadate, jasplakinolide, or LatA treatment on control (Ctrl) or Cav1 siRNA--transfected cells. Negative control IgG immunoprecipitation is shown. (C) MDA-231 cells were not treated (NT) or treated with PP2, Y27632, R0, or staurosporine (Stauro; left) or with PMA (right) and then Western blotted for pCav1, Cav1, cavin-1, and β-actin (\*\*, P \< 0.001). (D) MDA-231 cells treated with jasplakinolide or mechanically stretched (left) or treated with jasplakinolide and either PP2, Y27632, R0, or staurosporine (right) were Western blotted for Cav1, cavin-1, and β-actin. (E) MDA-231 cells transiently transfected with Cav1-luciferase or cavin-1--luciferase for 48 h were subjected to luciferase assay after treatment with PP2, Y27632, R0, staurosporine (Stauro), or PMA. (F) MDA-231 cells were cotransfected with Cav1-luciferase or cavin-1--luciferase and either control (siCtl) or Egr1 (siEgr1) siRNA and treated with jasplakinolide and either PP2, Y27632, R0, or staurosporine before luciferase assay (\*, P \< 0.05). Error bars show means ± SEM.](JCB_201207089_Fig5){#fig5}

To identify signaling pathways that mediate pCav1-Egr1 control of *Cav1* and *cavin-1* gene expression, we treated MDA-231 cells with the Src kinase inhibitor PP2, the ROCK inhibitor Y27632, and the PKC inhibitors R0 and staurosporine. In PP2- and Y27632-treated MDA-231 cells, pCav1 is no longer detected, as previously reported ([@bib21]), but pCav1 is still present in cells treated with the PKC inhibitors R0 and staurosporine. The PKC activator PMA does not affect pCav1 levels but does significantly increase Cav1 expression ([Fig. 5 C](#fig5){ref-type="fig"}). As observed for Cav1-expressing MDA-435 cells, both jasplakinolide treatment and cell stretching induce Cav1 expression in MDA-231 cells. All four kinase inhibitors reduce jasplakinolide induction of Cav1, although not cavin-1, levels ([Fig. 5 D](#fig5){ref-type="fig"}). This suggests that although PP2 and Y27632 prevent jasplakinolide induction of Cav1 by preventing Cav1 phosphorylation, PKC acts downstream of pCav1 to regulate actin-dependent induction of Cav1.

We then tested the effect of these drugs on Cav1 and cavin-1 promoter activity. PP2, Y27632, R0, and staurosporine reduce and PMA increases Cav1 and, to a lesser extent, cavin-1 promoter activity in untreated ([Fig. 5 E](#fig5){ref-type="fig"}) and jasplakinolide-treated ([Fig. 5 F](#fig5){ref-type="fig"}) MDA-231 cells. Src, ROCK, and PKC inhibition of jasplakinolide-induced Cav1 and cavin-1 promoter activity is not observed in Egr1 knockdown cells and therefore mediated by Egr1 ([Fig. 5 F](#fig5){ref-type="fig"}). Relative to Cav1, control of cavin-1 promoter activity and protein expression levels by pCav1 and Egr1 is reduced in MDA-231 cells ([Fig. 5, C--E](#fig5){ref-type="fig"}). Similarly, cavin-1 mRNA induction in Cav1Y14D and Y14R MDA-435 cells, while significant, is reduced in amplitude relative to Cav1 mRNA ([Fig. 3 A](#fig3){ref-type="fig"}). Differential impact on Cav1 and cavin-1 expression at both the mRNA and protein levels in MDA-231 cells may reflect cell-specific promoter regulation and protein stability. *Cav1* gene expression is regulated by NF-κB and SP1 ([@bib5]; [@bib46]), and pCav1-PKC-Egr1 may be one of multiple mechanisms that regulate Cav1 and cavin-1 expression. Indeed, *Cav1* and *cavin-1* gene expression is selectively induced in Cav1wt- but not control dsRed- or dominant-negative Cav1Y14F-transfected MDA-435 cells by actin stabilization, mechanical stretch, or Egr1 knockdown ([Figs. 2 C](#fig2){ref-type="fig"} and [3 D](#fig3){ref-type="fig"}). In the breast cancer cell models studied here, Egr1 transcriptional regulation of *Cav1* and *cavin-1* gene expression therefore requires pCav1 and is specific to Cav1-expressing cells.

Cav1 therefore represents a mechanosensor that transduces increased actin cytoskeleton--focal adhesion tension to regulate *Cav1* and *cavin-1* gene expression and thereby supply caveolae to buffer membrane tension in response to mechanical stress ([@bib42]). Endothelial Cav1 and caveolae are required for mechanotransduction in blood vessels ([@bib49]). Mechanical and oxidative stress induce Cav1 phosphorylation ([@bib47]; [@bib36]), including a role for p38 MAPK/Sp1 gene transcription ([@bib5]; [@bib46]). In cancer cells, tissue stiffness promotes malignancy through integrin-mediated focal adhesion and Rho/ROCK-generated contractility ([@bib35]). Together with pCav1 activation of RhoA and Rho/ROCK-dependent phosphorylation of Cav1 ([@bib13]; [@bib21]), this suggests that pCav1 may be a central regulator of a positive feedback loop that responds to mechanical stress and thereby promotes Rho/ROCK-dependent tumor cell migration.

In conclusion, we have identified a pathway linking force-induced phosphorylation of Cav1 with transcriptional regulation of key components of caveolar biogenesis. Posttranslational modification of Cav1 (i.e., Y14 tyrosine phosphorylation) enables it to function as a reporter of cellular tension that feedbacks to regulate, via Egr1 transcriptional regulation of Cav1 and cavin-1, the plasma membrane abundance of an organelle critical to the cellular response to mechanical stress.

Materials and methods
=====================

Antibodies and reagents
-----------------------

Antibodies to Egr1 and RhoA were obtained from Santa Cruz Biotechnology, Inc., to β-actin were obtained from Sigma-Aldrich, to Cav1 and cavin-1 were obtained from BD, and to pCav1 were obtained from Cell Signaling Technology. Alexa Fluor 488--phalloidin was purchased from Molecular Probes. Jasplakinolide, LatA, R0, staurosporine, PMA, hydrogen peroxide (H~2~O~2~), and sodium orthovanadate (Na~2~VO~4~) were obtained from Sigma-Aldrich. PP2 and Y27632 were obtained from EMD Millipore. Egr1-targeting SMARTpool siRNA was purchased from Thermo Fisher Scientific. OneStep StopGlo was obtained from Promega.

Plasmids, luciferase, and CHIP assays
-------------------------------------

C-terminal--tagged myc/mRFP-tagged Cav1wt, Y14F, Y14D, and Y14R under control of the cytomegalovirus promoter in pcDNA3 plasmid and cavin-1--GFP in pEGFP-N1 were as previously described ([@bib12]; [@bib15]; [@bib21]). Control pRL, Cav1-luciferase, and cavin-1--luciferase plasmids were purchased from SwitchGear, and their expression was assayed using a luciferase detection kit (Promega) and a luminometer (Lumat LB 9507; Berthold Technologies). CHIP assays were performed as previously described ([@bib20]). In brief, cells treated with 1% formaldehyde for 10 min at room temperature to cross-link protein--DNA complexes were harvested, washed three times with PBS, lysed in 1% SDS, 50 mM Tris-HCI, pH 8.1, and 1 mM EDTA, and sonicated twice (10 W for 15 s). Cell debris was pelleted at 4°C, and the supernatant was incubated with either 3 µg anti-Egr1 antibody or IgG in dilution buffer (0.01% SDS, 16.7 mM Tris-HCI, pH 8.1, 1.2 mM EDTA, 150 mM NaCl, and 1% Triton X-100) and rotated overnight at 4°C. Antibody DNA--protein complexes were pulled down with protein A--Sepharose beads, washed, and then decross-linked by incubating at 65°C for 4 h. DNA was ethanol precipitated, subjected to proteinase K treatment for 30 min at 37°C, and repurified before using for PCR. The following sets of primers were used to assess Egr1 binding to Cav1 or cavin-1 promoters: 5′-TGGAGAGGCAGATAGCAGAAGCGG-3′ and 5′-GATCTTCATTTCTTATTTCGAAGCG-3′; or 5′-TGCCCATCTTAATTCTACTCTGTTAGG-3′ and 5′-GACTTGATCAGCTCTTCTGAG-3′.

Cell lines, cell stretching, and drug treatment
-----------------------------------------------

Stable MDA-435 cell lines expressing dsRed, Cav1wt-mRFP, Cav1Y14F-mRFP, Cav1Y14R-mRFP, or Cav1Y14D-mRFP were generated as described previously ([@bib21]). In brief, 48 h after Effectene transfection, cells were selected with 400 µg/ml G418 for 2 wk, and resistant cells were FACS sorted. Cells were maintained in DME medium containing 10% FBS, penicillin/streptomycin, and 50 µg/ml geneticin (Gibco; Invitrogen). All cell lines were passaged at least twice after recovery from frozen stocks before initiating experiments and maintained in culture for a maximum of 8--10 passages to minimize phenotypic drift. For cyclic stretch experiments, cells were seeded and grown on untreated silicone elastomer-bottomed plates (Bioflex) overnight before subjecting them to cyclic stretch in a strain unit (FX-4000T Flexercell; FlexCell). Cells were exposed to an equiaxial stretch of 5% at a frequency of 1 Hz after a cycle of 30-min stretching and 30-min relaxation for a total of 36 repeats. Cells were treated with 3 mM hydrogen peroxide--1 mM sodium vanadate for 45--60 min to induce oxidative stress and with 150 nM LatA for 30 min to depolymerize actin microfilaments and jasplakinolide (MDA-231, 100 nm; MDA-435, 150 nm) for 2 h to stabilize the actin cytoskeleton ([@bib45]; [@bib39]). Cells transiently transfected with reporter constructs were treated 36--42 h after transfection. Where indicated, cells were treated with 5 µM PP2, 10 µM Y27632, 4 µM R0, 100 nM staurosporine, or 150 nM PMA for 2 h.

EM
--

Stable MDA-435 cell lines or transiently transfected Cav1^−/−^ immortalized MEFs expressing the indicated constructs were fixed in the presence of ruthenium red to highlight the cell surface ([@bib15]) and processed by conventional methods for Epon embedding. Cav1^−/−^ cells were sectioned parallel to the substratum, and images were captured using a transmission electron microscope (1011; JEOL) equipped with a cooled charge-coupled device camera (Morada; Olympus) and with AnalySIS software (Olympus) at a magnification of 15,000--20,000×. For quantification of caveolae density in MDA-435 cell lines, sections were cut perpendicular to the cell surface (vertical sections) to ensure random sampling of the entire plasma membrane. Complete cells were identified by EM, and the number of ruthenium red--labeled 55--70-nm uncoated circular profiles (i.e., caveolae) was counted per cell profile. Data were generated from analysis of ≥45 cell profiles per line (from three independent cultures of each line).

FLIM, immunofluorescence, cell spreading, Western blots, RhoA-GTP assay, and semiquantitative RT-PCR
----------------------------------------------------------------------------------------------------

FLIM of Cav1^−/−^ MEFs transfected with cavin-1--GFP (donor) and mRFP-Cav1wt and Y14 mutants (acceptor) was performed using a lifetime fluorescence imaging attachment (Lambert Instruments) on an inverted microscope (IX71; Olympus) as previously described ([@bib15]). Cells were excited using a sinusoidally modulated 3-W 470-nm light-emitting diode at 80 MHz under epi-illumination and imaged with a 60×, NA 1.45 oil objective using an appropriate GFP filter set. The phase and modulation were determined from a set of 12 phase settings, and pixel resolution of two lifetimes in the frequency domain was performed using the polar plot method as implemented in the manufacturer's software.

To label F-actin, cells were fixed with 3% paraformaldehyde and permeabilized with 0.1% Triton X-100 before incubation with Alexa Fluor 568--phalloidin. Coverslips were mounted in Airvol (Air Products, Inc.), and images were collected with the 100× Plan Apochromat objective, NA 1.35, of a confocal microscope (FV1000; Olympus). To quantify cell area, cells labeled with Alexa Fluor 568--phalloidin and Hoechst on 96-well plates were scanned using the 10× objective of an automated fluorescence microscope (ArrayScan; Cellomics, Inc.), and cell area was measured on five fields/well using the Morphology Explorer BioApplication software (Cellomics, Inc.) module as previously described ([@bib39]). Western blots and semiquantitative RT-PCR were as previously described ([@bib21]). Antibody dilutions for Western blots were as follows: 1:1,000 for pCav1, Cav1, and cavin-1, 1:500 for Egr1, 1:10,000 for β-actin, and 1:3,000 for HRP anti--mouse or anti--rabbit. RhoA-GTP pull-downs were performed with rhotekin beads according to the supplier's protocol (EMD Millipore) and probed by Western blotting for RhoA (active and total; 1:1,000 antibody dilution) as previously described ([@bib21]). Transcript levels were determined by PCR (25 cycles) from total cDNA using primer sets for Cav1, 5′-TCTCTACACCGTTCCCATCC-3′ and 5′-TCCCTTCTGGTTCTGCAATC-3′; cavin-1, 5′-CAAGGCCACCGAGATGGTGGA-3′ and 5′-GAAGTTCGGAAGGAGCGAGGA-3′; and glyceraldehyde 3-phosphate dehydrogenase, 5′-GGTCGGAGTCAACGGATTTGGTCG-3′ and 5′-CCTCCGACGCCTGCTTCACCAC-3′.

Online supplemental material
----------------------------

Fig. S1 shows Cav1 expression by Western blotting in the MDA-435 Cav1 Y14 transfectants relative to endogenous Cav1 in MDA-231 cells. Fig. S2 shows that Cav1^−/−^ MEF expression of mRFP-tagged Cav1wt, Y14F, Y14D, or Y14R induces caveolae by EM and their equivalent interaction with cavin-1--GFP by FLIM analysis. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201207089/DC1>.
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